Case reports: Worsening facial redness with flushing episodes

This patient presented with a red complexion, telangiectasia and intermittent flushing. By Dr Anshoo Sahota

Rosacea: most patients will require combination therapy (SPL)
Rosacea: most patients will require combination therapy (SPL)

This 55-year-old male patient had a six-year history of rosacea, manifesting as facial redness, which was intermittent at first, but had now become more fixed.

It was exacerbated by warm weather, embarrassment and consumption of alcohol or spicy food. He also described intermittent flushing episodes for the past four months, related to changes in ambient temperature.

The patient's facial redness was affecting his work, particularly in face-to-face meetings. He was otherwise well and was taking oral lymecycline daily for his rosacea.

Examination revealed a generally red complexion on the upper and middle face, with telangiectasia around the nose and central face. There were no papules, pustules or evidence of inflammatory dermatoses such as eczema or psoriasis.

In the absence of inflammation, facial redness usually represents erythemotelangiectatic (type 1) rosacea. Seborrhoeic dermatitis is an important differential and may coexist.

The pathogenesis of facial redness is not fully understood, but antimicrobial peptides with pro-inflammatory and angiogenic effects, such as cathelicidin LL-37, are thought to play a part in the aetiology. These are induced by injury, such as sunlight exposure, and by vitamin D. There is also evidence that the Demodex mite and the bacterium it carries have a significant role in rosacea.

Neurovascular function is key to the vasodilation and flushing seen in type 1 rosacea; there is upregulation of capsaicin receptors in cutaneous nerves (with increased sensitivity to spicy food) and increased activity of VEGF-A, correlating with increased skin vascularity.

Patients with facial redness often have 'sensitive' skin, which easily becomes red or flushed. The stimulants for redness include physical and psychological triggers, such as rapid changes in temperature, sunlight, exposure to cold weather and psychological stress. Ingested triggers include alcohol, hot/spicy food, caffeinated drinks and citrus fruits. Often, such patients experience a 'burning' sensation when topical products (including emollients) are applied to the skin.


This patient's treatment was continued with oral lymecycline to maintain control of the papular and pustular component of the rosacea. Additional options were considered for both the recent onset flushing and the fixed facial redness.

Initial treatment for the flushing was 100 microgram oral clonidine three times per day, rising after three to four days to 200 microgram three times per day. The aim was a maximum 1,200 microgram per day in three divided doses, but the side-effect of a dry mouth prevented him from taking more than 200 microgram three times per day.

He was prescribed topical brimonidine gel for intermittent treatment of his fixed facial redness, and recommended to have pulsed dye laser treatment for the telangiectasia.

Therapeutic options

Treatment choices for facial redness have been fairly limited until recently. Despite being effective in papulopustular rosacea (type 2 rosacea), oral and/or topical antibiotics have little effect on the facial redness of rosacea.

Previously, the main therapeutic options for facial redness were physical treatments, such as vascular-specific pulsed dye laser or intense pulsed light. These can bring long-lasting improvement, but are costly and can be painful, causing temporary bruising or occasionally, scarring.

Systemic agents acting on the adrenergic system, including non-selective beta-blockers such as propranolol or carvedilol, may have a role in anxiety-related flushing, although they are rarely successful for fixed facial redness. Alpha-adrenergic agonists, such as clonidine or moxonidine, can also help in facial flushing by reducing sympathetic tone centrally, but often have troublesome side-effects, such as drowsiness and fatigue. Clonidine in particular has to be used with care and dose escalation and reduction must be gradual.

Topical agents, such as brimonidine and oxymetazoline, offer an alternative approach. Both are selective alpha-2 adrenergic agonists, acting as peripheral vasoconstrictors.

A recently developed topical preparation of brimonidine 3mg/g gel has a formulation that allows effective skin penetration and provides temporary vasoconstriction in the skin. It reaches maximal effect after two hours and can lessen visible facial redness for eight to 12 hours. It has a low incidence of adverse effects or rebound vasodilation. However, it has little or no effect on telangiectasia or facial flushing.

Most patients with facial redness from rosacea will need a combination of treatments, including oral antibiotics for papules and pustules, systemic vasoconstrictors for flushing, topical vasoconstrictors for facial redness and vascular-specific laser for telangiectasia.

  • Dr Anshoo Sahota is a consultant dermatologist, Whipps Cross University Hospital and Barts and the London NHS Trust

Competing interests: None declared

Read these next

Psychological care: Quality of life assessment in skin disease

Psychological care: Quality of life assessment in skin disease

Patients should be assessed for the impact on their...

New topical treatment for erythema of rosacea

New topical treatment for erythema of rosacea

Mirvaso (brimonidine) is a 3mg/g topical gel formulation...

Aesthetic dermatology: Treatment of facial telangiectasia

Aesthetic dermatology: Treatment of facial telangiectasia

Facial telangiectasia can be distressing but the condition...

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.